Researchers developed a “tumor-dressed” dendritic cell concept that combines expandable, genetically modifiable human induced pluripotent stem cells with tumor-membrane dressing to display tumor-derived MHC–antigen complexes. The approach, proposed by investigators at UCSF, is designed to prime both naive and effector T cells while reducing susceptibility to natural killer cell-mediated destruction. The strategy is aimed at enabling scalable personalization by using patient- or tumor-derived membrane components while standardizing the manufacturing of a stem-cell-derived platform. For immunotherapy development, the concept targets a common manufacturing and efficacy bottleneck: creating individualized antigen presentation with consistent quality at scale. Key follow-through will be proof of tumor antigen breadth, persistence of induced immunity, and whether the NK shielding translates into improved in vivo performance.